TLPH
Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Board Member
2025-10-23–present
Board Member
Talphera, Inc. (TLPH)Equibles does not estimate personal net worth.
Get an email with a short summary when Talphera, Inc. publishes a filing, an earnings call transcript or a press release.
Get TLPH alertsVincent J. Angotti is recorded as Board Member at Talphera, Inc. (TLPH) since October 23, 2025 and CEO at Talphera, Inc. (TLPH). The newest filing on record that lists Vincent J. Angotti as CEO and Board Member at Talphera, Inc. (TLPH) is dated April 29, 2026. Talphera, Inc. reported in an 8-K filed October 24, 2025 that Vincent J. Angotti was appointed Class II director, effective October 23, 2025. The proxy statement of Talphera, Inc. reports total compensation of $1,117,277 for Vincent J. Angotti in fiscal 2025, including a base salary of $688,811. Disclosed compensation is on record for 9 fiscal years. Vincent J. Angotti has spoken on 13 earnings calls across 1 company, most recently for Talphera, Inc. on November 12, 2026. Talphera, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Talphera, Inc. includes Raffi Asadorian (CFO), Abhinav Jain (Board Member), Adrian Adams (Board Member) and 7 others.
“Vincent J. Angotti, Stephen J. Hoffman, M.D., Ph.D. and Abhinav Jain were elected as Class II directors, by a plurality of the votes entitled to vote on the election of directors, to hold office until the 2028 Annual Meeting of Stockholders by the following vote:”
“I'll begin with an update on our nephroCRRT registrational study evaluating NIAD, our investigational nephamostat-based regional anticoagulant for use in the extracorporeal circuit during continuous renal replacement therapy, or CRRT.”
“We remain on track to complete enrollment in the NefroCRRT study later this year. This registrational trial is designed to evaluate whether the Nefamistat is a safe and effective anticoagulant for use during continuous renal replacement therapy, or CRRT.”
“It's been less than two months since our last update, and we're excited about the progress we've made this year in the NEPHRO study with our ongoing enrollment at current clinical study sites, activation of additional sites, achievement of the 50% enrollment milestone, and consequently, the closure of an additional…”
“We are excited about the progress made this past quarter, specifically in the continued nephro study enrollment at our current clinical study sites and completing the financing that, with the additional tranches, provides us sufficient capital for a planned approval of the NIAID PMA later next year.”
“We're excited about the progress made this past quarter, specifically in the acceleration of the NEPHRO study enrollment.”
2025-10-23–present
Last confirmed April 29, 2026
Start not stated–present
Last confirmed April 29, 2026
TLPH
Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Board Member
2025-10-23–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Talphera, Inc. (TLPH) | CEO | $688,811 | $1,117,277 |
| 2024 | Talphera, Inc. (TLPH) | CEO | $668,749 | $1,038,992 |
| 2023 | Talphera, Inc. (TLPH) | CEO | $655,636 | $1,211,994 |
| 2022 | Talphera, Inc. (TLPH) | CEO | $636,540 | $1,297,016 |
| 2021 | Talphera, Inc. (TLPH) | CEO | $636,540 | $2,447,954 |
| 2020 | Talphera, Inc. (TLPH) | CEO | $636,540 | $1,765,522 |
| 2019 | Talphera, Inc. (TLPH) | CEO | $618,000 | $2,125,052 |
| 2018 | Talphera, Inc. (TLPH) | CEO | $600,000 | $1,738,845 |
| 2017 | Talphera, Inc. (TLPH) | CEO | $493,461 | $2,353,923 |